News

The National Institute for Health and Care Excellence has published a new draft guideline to help healthcare professionals better recognise the signs of sepsis and thus accelerate access to treatment.

The National Institute for Health and Care Excellence has updated tuberculosis guidelines under a drive to eradicate the disease from the country.

Pfizer is linking arms with non-profit group The California Institute for Biomedical Research in a collaboration focused on the development of novel antibody-based therapeutics for heart failure. 

AstraZeneca’s biologics R&D arm MedImmune is strengthening its links with the University of California, San Francisco, in a research collaboration focused on respiratory, inflammation and autoimmunity.

Use of Roche’s high-speed heart attack test, which “drastically shortens” time to diagnosis and thus facilitates faster treatment and potentially better outcomes, has been validated in a three-year clinical trial involving more than 1,200 patients.

AbbVie’s venetoclax will be reviewed by both US and EU regulators as a potential first-in-class treatment for certain adults with chronic lymphocytic leukaemia.

MSD has snapped up British drug discovery group IOmet, securing access to a new batch of preclinical cancer candidates to help stock up its early R&D pipeline.

More than 4,000 operations across the National Health Service in England are reportedly being rescheduled as the first doctor’s strike in 40 years gets underway.

Eisai has submitted an application to market its oncology drug lenvatinib for the treatment of patients with renal cell carcinoma.

AstraZeneca and its biologics R&D arm MedImmune have signed a deal with Moderna Therapeutics to discover, co-develop and co-commercialise messenger RNA-based therapeutics targeting a range of cancers.

Cost regulators for the National Health Service in Scotland have approved funding for six new therapies, giving new options to patients with cancer, kidney disease and diabetes.

Following months of speculation Shire has now confirmed that it is buying Baxter spin-out Baxalta in a deal valued at around $32 billion, creating the world’s leading global biotech and rare disease specialist.

Sanofi has extended and reshaped its existing collaboration with Warp Drive Bio centred on its proprietary SMART and Genome Mining platforms to discover new antibiotics and therapeutics for cancer.

Prime Minister David Cameron has announced that the government is to spend nearly £1 billion on improving mental health services across the country. 

Pfizer is streaming $46 million into four early-stage research companies ‘on the leading edge of scientific innovation’, under wider plans to expand its R&D investment strategy.